In a pooled analysis of 2578 patients who received RTX together with methotrexate in clinical trials for RA (some of whom received RTX for up to five cycles over six years), 23%, 5% and 1% of patients developed levels of IgM, IgG, and IgA below the lower normal limit (LNL), respectively. Here, CD79A is linked to rheumatoid arthritis.